Navigation Links
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Date:10/22/2007

trial was not designed to analyze statistical differences in any of the sub-groups, including diabetic patients.

"The results from XIENCE V represent an important advancement for patients with coronary artery disease," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "As a next generation drug eluting stent, XIENCE V continues to demonstrate longer-term safety and consistently superior efficacy results across the SPIRIT trials with the potential to raise the bar for all DES."

About XIENCE V

The XIENCE V system utilizes everolimus, which has been shown to reduce tissue proliferation in the coronary vessels following stent implantation, and is based upon the highly deliverable and proven MULTI-LINK VISION coronary stent platform.

XIENCE V was launched in Europe and Asia Pacific in 2006. XIENCE V is currently an investigational device in the United States and Japan. Results from the SPIRIT III trial are intended to support U.S. Food and Drug Administration (FDA) approval of the XIENCE V Stent System and Ministry of Health and Welfare approval in Japan. Abbott anticipates receiving XIENCE V U.S. FDA approval in the first half of 2008.

Abbott supplies a private-label version of XIENCE V, called the PROMUS(TM) Everolimus-Eluting Coronary Stent System, to Boston Scientific as part of a distribution agreement established between the two companies last year.

About the SPIRIT Family of Trials

SPIRIT FIRST was a first-in-man study comparing the XIENCE V Everolimus Eluting Coronary Stent System with the MULTI-LINK VISION metallic stent system. SPIRIT FIRST demonstrated positive results with one MACE event at one year and no additional MACE events out to three years. In addition, the number of late stent thromboses in the XIENCE V arm of the SPIRIT FIRST trial was zero out to three years of clinical follow-up.

SPIRIT II is a 300-patient randomized, single-blind, prospective clinical trial evaluating XIE
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
2. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
3. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
4. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
5. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
7. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
8. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...wswire-FirstCall/ -- , - Not for UK Journal... Products for Human Use (CHMP) today,announced it...el(R),(etanercept) as a treatment for children ag...laque psoriasis. If approved by the European,Comm...Enbrel will become the,first biologic treatment i...
(Date:11/20/2008)...Nov. 20 GlaxoSmithKline (...es Food and Drug Administration (FDA) granted acce... the treatment of thrombocytopenia in patients wit...pura (ITP) who have had an insufficient response t... The approval is a significant milestone for PROMA...
(Date:11/20/2008)...FirstCall/ -- Duska Therapeutics,Inc., (OTC Bull...mitted its,pivotal Phase 3 ATPace clinical trial ...ssment (SPA) procedure with the U.S. Food and Drug...ng an agreement with the FDA, Duska intends to ini...o-controlled and randomized Phase 3,clinical tria...
(Date:11/19/2008)... Posit Science Corporation,researcher, Dan Tinker...ce,Annual Conference in Washington, DC this week ...by Boomers. The computerized brain plasticity-bas...ises that target auditory and,language systems. ...mprovements in cognition by improving speed and ac...
Breaking Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Location location location important for genes too 4646 1Location location location important for genes too 4646 2VentriPoint Diagnostics Files Management Discussion and Analysis Unaudited Financial Results for 2Q 2008 7393 1VentriPoint Diagnostics Files Management Discussion and Analysis Unaudited Financial Results for 2Q 2008 7393 2Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care 3A Carilion Clinic Teams Up with Retasure 7389 1Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care 3A Carilion Clinic Teams Up with Retasure 7389 2Dr Joel Aronowitz Specialist in Los Angeles Body Lift Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 25871 1Dr Joel Aronowitz Specialist in Los Angeles Body Lift Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 25871 2Dr Joel Aronowitz Specialist in Los Angeles Body Lift Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 25871 3Dr Joel Aronowitz Specialist in Los Angeles Body Lift Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 25871 4
...2007 /PRNewswire/ -- Addex Pharmaceuticals,announc...proof of,concept trial with its lead compound ADX1... its primary objective, the absence of,pain at 2 h...and,also showed trends towards improvement in pain...ther time points. ADX10059 has,already recently de...
...WIRE)--Apr 19, 2007 - Gilead Sciences, Inc.,(Nasda...ase III,AIR-CF2 study evaluating aztreonam lysine ...stic fibrosis (CF) who have,pulmonary Pseudomonas ... treatment course of aztreonam lysine significantl...nous (IV) antibiotics versus,placebo. All patients...
Other Medicine Technology:Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 2Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 3Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7
(Date:11/22/2008)...o enough to protect themselves from stroke, heart ...News) -- It,s one of medicine,s mantras: If you ha...ill have a dramatic impact on your risk of stroke,...ople with high blood pressure still aren,t doing a...S. Centers for Disease Control and Prevention stud...
(Date:11/21/2008)... new therapies for preterm labor , , FRI...hey,ve found the switch that activates the uterine...ing that may lead to therapies for preterm labor. ... protein IP on the surface of these uterine muscle...egnancy. , But researchers from Dartmouth Medi...
(Date:11/21/2008)...v. 21 During a memoria... G. Rendell today remembered Lieutenant Governor C...ortant partner in public service, and a tireless a... "As the first woman elected lieutenant governor, ... said Governor Rendell. "Her family and her faith ...
(Date:11/21/2008)...l proved effective against Lennox-Gastaut syndrome... A new drug called Banzel (rufinamide) has been ap...orm of epilepsy called Lennox-Gastaut syndrome, th...ay. , The approval was based on results of a fo...s 4 to 30. Compared to patients who took a placebo...
Breaking Medicine News(10 mins):Health News:High Blood Pressure Stalks Many Americans 2Health News:High Blood Pressure Stalks Many Americans 3Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 2Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...AIDS in the early 1990's when she was 35, healthy,...d years earlier// of AIDS related complications, h...her less than two years to live. One day, flippi...eople, she saw an advertisement offering to buy he...
...a close friend of President Bush, a businessman-...itchman// on the president's health care proposals...th costs. He is promoting Bush's proposals to prov...... and make hospitals and doctors prices availabl...
...atisfied with their health care despite the fact t... other industrialized nations//. These were the re...d on Tuesday. In 2004 the survey revealed that Un... on medical care almost twice as much as other ind...
...iting crowd of 80,000 and the humid weather, the f... can feel cheerful about here are a spruced up// a...one-day cricket match between England and India ta...ernational Stadium Thursday. The teams were given ...
Other Medicine News:
The NU-5510 DHD AutoFlow Direct Heat Decontamination CO2 Incubator provides continuous HEPA filtration guarantying the greatest control of airborne contaminants. The dual decontamination cycles, both
...al-sized CO2 incubator with 6-sided direct heating...er-weight incubator with greater internal storage ...ss, convection air circulation optimizes culture c...al viewing window means cultures need not be distu...
...te-sized CO2 incubator with 6-sided direct heating...er-weight incubator with greater internal storage ...filtered CO2 inlet, heated outer door with glass i... optimize culture conditions and minimize contamin...
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO2 Incubator
Medicine Products: